SG11201809005TA - Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer - Google Patents

Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer

Info

Publication number
SG11201809005TA
SG11201809005TA SG11201809005TA SG11201809005TA SG11201809005TA SG 11201809005T A SG11201809005T A SG 11201809005TA SG 11201809005T A SG11201809005T A SG 11201809005TA SG 11201809005T A SG11201809005T A SG 11201809005TA SG 11201809005T A SG11201809005T A SG 11201809005TA
Authority
SG
Singapore
Prior art keywords
suite
international
massachusetts
cambridge
alk
Prior art date
Application number
SG11201809005TA
Inventor
Johan Karl Olov Skog
Mikkel Noerholm
Kay Brinkman
Elena Castellanos-Rizaldos
James Hurley
Original Assignee
Exosome Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exosome Diagnostics Inc filed Critical Exosome Diagnostics Inc
Publication of SG11201809005TA publication Critical patent/SG11201809005TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/101—Reactions characterised by their quantitative nature the purpose being quantitative analysis with an internal standard/control
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110111111110111011111111001111101111011111 International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ...... ... WO 2017/181183 Al 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: (74) Agents: KARNAKIS, Jennifer A. et al.; COOLEY LLP, C12Q 1/68 (2006.01) Attn: Patent Group, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US). (21) International Application Number: PCT/US2017/027944 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 17 April 2017 (17.04.2017) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (25) Filing Language: English DO, HN, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (26) Publication Language: English KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (30) Priority Data: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 62/322,982 15 April 2016 (15.04.2016) US NI, RU, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (71) Applicant: EXOSOME DIAGNOSTICS, INC. [US/US]; TH, Riverside Technology Center, 840 Memorial Drive, Suite ZA, ZM, ZW. 3, Cambridge, Massachusetts 02139 (US). TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (84) Designated States (unless otherwise indicated, for every (72) Inventors: SKOG, Johan Karl Olov; c/o Exosome Dia- kind gnostics, Inc., 840 Memorial Drive, Suite 3, Cambridge, GM, Massachusetts 02139 (US). NOERHOLM, Mikkel; c/o TZ, of regional protection available): ARIPO (BW, GH, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Exosome Diagnostics GmbH, Am Klopferspitz 19a, 82152 TJ, Martinsried (DE). BRINKMAN, Kay; c/o Exosome Dia- DK, _ TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, — _ gnostics, Inc., 840 Memorial Drive, Suite 3, Cambridge, LV, Massachusetts 02139 (US). CASTELLANOS-RIZAL- SM, DOS, Elena; c/o Exosome Diagnostics, Inc., 840 Memori- GW, KM, ML, MR, NE, SN, TD, TG). al Drive, Suite 3, Cambridge, Massachusetts 02139 (US). MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, = HURLEY, James; c/o Exosome Diagnostics, Inc., 840 Published: Memorial Drive, Suite 3, Cambridge, Massachusetts 02139 — with international search report (Art. 21(3)) (US). = = = = = = = = = 1-1 M GC Il Il GC Il IN Il © (54) Title: PLASMA-BASED DETECTION OF ANAPLASTIC LYMPHOMA KINASE (ALK) NUCLEIC ACIDS AND ALK FU- \" SION TRANSCRIPTS AND USES THEREOF IN DIAGNOSIS AND TREATMENT OF CANCER C ) .,.. (57) : The present invention relates generally to the field of biomarker analysis, particularly determining gene expression signatures from biological samples, including plasma samples.
SG11201809005TA 2016-04-15 2017-04-17 Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer SG11201809005TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322982P 2016-04-15 2016-04-15
PCT/US2017/027944 WO2017181183A1 (en) 2016-04-15 2017-04-17 Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
SG11201809005TA true SG11201809005TA (en) 2018-11-29

Family

ID=58707999

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809005TA SG11201809005TA (en) 2016-04-15 2017-04-17 Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer

Country Status (7)

Country Link
US (1) US20190093172A1 (en)
EP (1) EP3443117A1 (en)
JP (1) JP2019513391A (en)
KR (1) KR20190020649A (en)
CN (1) CN109563547A (en)
SG (1) SG11201809005TA (en)
WO (1) WO2017181183A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109266740A (en) * 2017-07-14 2019-01-25 中国科学院上海生命科学研究院 For pulmonary cancer diagnosis or the marker and diagnostic reagent of prognosis
US11345957B2 (en) 2017-07-18 2022-05-31 Exosome Diagnostics, Inc. Methods of treating glioblastoma in a subject informed by exosomal RNA signatures
KR101987065B1 (en) * 2017-08-07 2019-06-10 주식회사 싸이토젠 A method for analyzing eml4-alk gene variance
KR102080887B1 (en) * 2017-11-07 2020-02-24 고려대학교 산학협력단 Composition for diagnosing or prognosing lung cancer including exosome based gcc2 gene and protein
CN107653320A (en) * 2017-11-15 2018-02-02 深圳华大生命科学研究院 EML4 ALK fusion gene noninvasive detection kits
CN109628599B (en) * 2019-01-08 2022-06-07 大连医科大学附属第二医院 ALK fusion gene detection and typing kit based on sandwich method high-resolution melting curve analysis
CN111467493A (en) * 2019-01-23 2020-07-31 首都师范大学 Human REV 3L protein cleavage inhibitor and application thereof
WO2020204665A1 (en) * 2019-04-03 2020-10-08 고려대학교 산학협력단 Marker composition for diagnosing cancer or predicting prognosis on basis of exosome overexpressing tuba1c protein
KR102350603B1 (en) * 2019-04-03 2022-01-14 고려대학교 산학협력단 Composition for diagnosing or prognosing cancer including exosome based tuba1c proteins
CN110257537B (en) * 2019-07-04 2023-03-24 大连晶泰医学检验实验室有限公司 Liquid phase hybridization capture library for syphilis pathogen detection and construction method thereof
CN111041093B (en) * 2019-07-09 2021-11-23 江苏医药职业学院 Application of reagent for detecting expression level of coiled coil domain protein 127 and kit
CN110358830B (en) * 2019-07-11 2021-11-30 江苏医药职业学院 Application of reagent for detecting expression level of open reading frame 53 of chromosome 8 and kit
CN110358831B (en) * 2019-07-11 2021-12-24 江苏医药职业学院 Application of reagent for detecting expression level of transmembrane protein 41A and kit
CN110672848A (en) * 2019-10-25 2020-01-10 四川大学华西医院 Application of APEH autoantibody detection reagent in preparation of lung cancer screening kit
CN111068056A (en) * 2019-12-31 2020-04-28 天津医科大学肿瘤医院 Application of human DNAJC24 gene and related product
CN111394516A (en) * 2020-03-19 2020-07-10 申联生物医药（上海）股份有限公司 Internal reference gene for respiratory tract RNA virus PCR detection and detection product thereof
CN111529690B (en) * 2020-06-17 2023-03-31 中国科学院昆明动物研究所 New application of human CD133 protein 1-108 peptide fragment
CN113462775B (en) * 2021-06-21 2023-06-27 华中农业大学 Gene markers for prognosis evaluation of colorectal cancer
CN113444779B (en) * 2021-08-05 2023-03-14 上海思路迪生物医学科技有限公司 Method for quantitative correction of exosome mRNA detection
CN113960313B (en) * 2021-12-22 2022-04-12 上海思路迪医学检验所有限公司 Exosome ALK fusion protein magnetic immunochemiluminescence detection kit
CN114921568B (en) * 2022-05-30 2023-04-07 西北农林科技大学 SNP molecular marker related to Qinchuan cattle body ruler and meat quality traits and application thereof
CN115927564B (en) * 2022-09-29 2023-09-12 杭州联川基因诊断技术有限公司 Primer combination, kit and method for detecting gene fusion in biological sample

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639611A (en) 1988-12-12 1997-06-17 City Of Hope Allele specific polymerase chain reaction
US5219727A (en) 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
CA2218875C (en) 1991-07-23 2000-11-07 The Research Foundation Of State University Of New York Improvements in the in situ pcr
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5556773A (en) 1993-08-06 1996-09-17 Yourno; Joseph Method and apparatus for nested polymerase chain reaction (PCR) with single closed reaction tubes
CA2270132A1 (en) 1996-11-06 1998-05-14 Sequenom, Inc. Dna diagnostics based on mass spectrometry
WO1998054571A1 (en) 1997-05-28 1998-12-03 The Walter And Eliza Hall Institute Of Medical Research Nucleic acid diagnostics based on mass spectrometry or mass separation and base specific cleavage
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
FR2788780B1 (en) 1999-01-27 2001-03-30 Ap Cells Inc PROCESS FOR THE PREPARATION OF MEMBRANE VESICLES
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
US6812023B1 (en) 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
US6913879B1 (en) 2000-07-10 2005-07-05 Telechem International Inc. Microarray method of genotyping multiple samples at multiple LOCI
US6696271B2 (en) 2001-08-23 2004-02-24 The Regents Of The University Of California Frozen tissue microarray technology for analysis of RNA, DNA, and proteins
WO2003023065A1 (en) 2001-09-06 2003-03-20 Syngenta Participations Ag Dna methylation patterns
CA2489360C (en) 2002-06-26 2013-01-29 Cold Spring Harbor Laboratory Methods and compositions for determining methylation profiles
AU2003267065A1 (en) 2002-09-02 2004-03-19 Pamgene B.V. Novel integrated microarray analysis
US7141371B2 (en) 2002-09-06 2006-11-28 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for detecting and localizing DNA mutations by microarray
EP1869221A2 (en) 2005-04-15 2007-12-26 Cedars-Sinai Medical Center Flow-cytometric heteroduplex analysis for detection of genetic alterations
EP4219762A1 (en) * 2008-02-01 2023-08-02 The General Hospital Corporation Use of microvesicles in diagnosis and prognosis of medical diseases and conditions
US9175350B2 (en) * 2009-12-22 2015-11-03 Quest Diagnostics Investments Incorporated EML4-ALK translocations in lung cancer
CN102719525B (en) * 2012-04-12 2014-06-04 厦门艾德生物医药科技有限公司 Primer, probe and detection kit for detection of EML4-ALK fusion gene mutation
CN103805684B (en) * 2012-11-09 2016-04-27 益善生物技术股份有限公司 The PCR primer that EML4-ALK fusion gene detects, test kit and liquid-phase chip
CN105026911B (en) 2013-01-03 2019-01-22 外来体诊断公司 Method for separating microcapsule bubble
CN103468813B (en) * 2013-09-17 2015-06-03 广州达健生物科技有限公司 EML4-ALK (Echinoderm microtubule associated protein like4-anaplastic lymphoma kinase) fusion gene fluorescent quantitative PCR (polymerase chain reaction) assay kit
EP3623792B1 (en) 2014-07-09 2021-09-01 Exosome Diagnostics, Inc. Methods for isolating microvesicles and extracting nucleic acids from biological samples
CN105039580A (en) * 2015-09-06 2015-11-11 武汉海吉力生物科技有限公司 Human ALK fusion gene detection primer set and detection kit

Also Published As

Publication number Publication date
CN109563547A (en) 2019-04-02
JP2019513391A (en) 2019-05-30
WO2017181183A1 (en) 2017-10-19
EP3443117A1 (en) 2019-02-20
KR20190020649A (en) 2019-03-04
US20190093172A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
SG11201809005TA (en) Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer
SG11201809913PA (en) Methods for detecting target nucleic acids in a sample
SG11201900509YA (en) Simultaneous capturing of overlay signals from multiple targets
SG11201808990QA (en) Compositions for topical application of compounds
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201903155XA (en) Pharmaceutical compounds
SG11201805592RA (en) Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201809522WA (en) Method of nucleic acid sequence determination
SG11201907162TA (en) Methods for cell-type specific profiling to identify drug targets
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201807249YA (en) Planar-beam, light detection and ranging system
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201808528VA (en) Modified wound dressings
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201809051YA (en) Cell retention device and method
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201807325UA (en) Optimizing range of aircraft docking system
SG11201805204WA (en) Nicotine particle capsule
SG11201901228QA (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
SG11201905640XA (en) Oncogenic splice variant determination
SG11201908767QA (en) Method for accurate diagnosis of a disease targeting biomarkers in liquid biopsy
SG11201903202VA (en) Osmotic membrane